Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

被引:12
|
作者
Smith-Apeldoorn, Sanne Y. [1 ]
Veraart, Jolien K. E. [1 ,2 ]
Ruhe, Henricus G. [1 ,3 ]
Rot, Marije Ann Het [4 ]
Kamphuis, Jeanine [1 ]
de Boer, Marrit K. [1 ]
Schoevers, Robert A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands
[2] Parnassia Psychiat Inst, Dept Mood Disorders, PsyQ Haaglanden, The Hague, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Nijmegen, Netherlands
[4] Univ Groningen, Dept Psychol, Groningen, Netherlands
来源
BJPSYCH OPEN | 2021年 / 8卷 / 01期
关键词
Esketamine; oral administration; treatment-resistant depression; tolerability; safety; ELECTROCONVULSIVE-THERAPY; BIPOLAR DEPRESSION; DOUBLE-BLIND; KETAMINE USE; S-KETAMINE; UNIPOLAR; EFFICACY; ANTIDEPRESSANT; METAANALYSIS; NORKETAMINE;
D O I
10.1192/bjo.2021.1059
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Intravenous infusion of ketamine can produce rapid and large symptom reduction in patients with treatment-resistant depression (TRD) but presents major obstacles to clinical applicability, especially in community settings. Oral esketamine may be a promising addition to our TRD treatment armamentarium. Aims To explore the safety, tolerability and potential clinical effectiveness of a 3-week treatment with repeated, low-dose oral esketamine. Method Seven patients with chronic and severe TRD received 1.25 mg/kg generic oral esketamine daily, over 21 consecutive days. Scores on the Systematic Assessment for Treatment Emergent Events (SAFTEE), Community Assessment of Psychic Experiences (CAPE), Clinician Administered Dissociative States Scale (CADSS) and Hamilton Rating Scale for Depression (HRSD) instruments, as well as blood pressure and heart rate, were repeatedly assessed. Results Treatment with oral esketamine was well-tolerated. No serious side-effects occurred, and none of the participants discontinued treatment prematurely. Psychotomimetic effects were the most frequently reported adverse events. Mean HDRS score decreased by 16.5%, from 23.6 to 19.7. Three participants showed reductions in HDRS scores above the minimum clinically important difference (eight-point change), of whom two showed partial response. No participants showed full response or remission. Conclusions These results strengthen the idea that oral esketamine is a safe and well-tolerated treatment for patients with chronic and severe TRD, but therapeutic effects were modest. Results were used to design a randomised controlled trial that is currently in progress.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
    Breeksema, Joost J.
    Niemeijer, Alistair
    Kuin, Bouwe
    Veraart, Jolien
    Vermetten, Eric
    Kamphuis, Jeanine
    van den Brink, Wim
    Schoevers, Robert
    PSYCHOPHARMACOLOGY, 2023, 240 (07) : 1547 - 1560
  • [32] Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
    Jamieson, Carol
    Popova, Vanina
    Daly, Ella
    Cooper, Kimberly
    Drevets, Wayne C. C.
    Rozjabek, Heather M. M.
    Singh, Jaskaran
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2023, 21 (01)
  • [33] Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study
    Brendle, Madeline
    Ahuja, Sachin
    Della Valle, Maisa
    Moore, Claire
    Thielking, Paul
    Malone, Daniel C.
    Robison, Reid
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (18) : 1323 - 1336
  • [34] Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity
    Lucchese, Ana C.
    Sarin, Luciana M.
    Muniz Magalhaes, Eduardo J.
    Del Sant, Lorena C.
    Puertas, Camila B.
    Tuena, Marco A.
    Nakahira, Carolina
    Fava, Victor A. R.
    Delfino, Rodrigo
    Surjan, Juliana
    Steiglich, Matheus S.
    Barbosa, Matheus
    Abdo, Guilherme
    Cohrs, Frederico M.
    Liberatori, Aroldo
    Del Porto, Jose A.
    Lacerda, Acioly L. T.
    Andreoli, Sergio B.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (02) : 142 - 149
  • [35] Intranasal esketamine for treatment-resistant depression
    Sobieraj, A.
    Wang, E.
    Kohl, P.
    Kirsch, B.
    Slapakova, L.
    Schuele, C.
    Falkai, P.
    EUROPEAN PSYCHIATRY, 2020, 63 : S117 - S117
  • [36] Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies
    Morrison, Randall L.
    Singh, Jaskaran
    Daly, Ella
    Fedgchin, Maggie
    Ochs-Ross, Rachel
    Karcher, Keith
    Lane, Rosanne
    Cooper, Kim
    Sanacora, Gerard
    Maruff, Paul
    Drevets, Wayne C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2024, 27 (11):
  • [37] Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
    Reif, Andreas
    Bitter, Istvan
    Buyze, Jozefien
    Cebulla, Kerstin
    Frey, Richard
    Fu, Dong-Jing
    Ito, Tetsuro
    Kambarov, Yerkebulan
    Llorca, Pierre-Michel
    Oliveira-Maia, Albino J.
    Messer, Thomas
    Mulhern-Haughey, Siobhan
    Rive, Benoit
    von Holt, Christian
    Young, Allan H.
    Godinov, Yordan
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1298 - 1309
  • [38] Pilot Study of Accelerated Low-Frequency Right-Sided Transcranial Magnetic Stimulation for Treatment-Resistant Depression
    Tor, Phern-Chern
    Galvez, Veronica
    Goldstein, James
    George, Duncan
    Loo, Colleen K.
    JOURNAL OF ECT, 2016, 32 (03) : 180 - 182
  • [39] Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
    Calder, Cameron N.
    Kwan, Angela T. H.
    Teopiz, Kayla M.
    Wong, Sabrina
    Rosenblat, Joshua D.
    Mansur, Rodrigo B.
    Rhee, Taeho Greg
    Ho, Roger
    Cao, Bing
    Mcintyre, Roger S.
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 356 : 753 - 762
  • [40] Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
    Takahashi, Nagahide
    Yamada, Aya
    Shiraishi, Ayako
    Shimizu, Hiroko
    Goto, Ryosuke
    Tominaga, Yushin
    BMC PSYCHIATRY, 2021, 21 (01)